IMC-F106C Shows Potential as T-cell Receptor–Driven Therapy in Melanoma
Source: OncLive, October 2022
Results from a first-in-humanphase 1 trial (NCT04262466) evaluating the efficacy and safety of IMC-F106C in patients with PRAME-positive metastatic/unresectable tumors showed a significant clinical benefit with the first PRAME×CD3 ImmTAC therapy, and could specifically fulfill unmet needs for patients with melanoma, according to Omid Hamid, MD.
The findings, which were presented during the ESMO Congress 2022, showed that 7 of 31 patients across malignancies who received IMC-F106C produced a partial response (PR) lasting up to 9 months, while 90% of patients (n = 18) experienced a reduction in ctDNA across multiple tumor types. Thirteen patients (65%) had a 50% reduction in ctDNA.
Specifically, 3 PRs were observed in patients with tebentafusp-naïve uveal melanoma and 2 PRs were seen in those with cutaneous melanoma.